[1] BOUCLY A, GERGES C, SAVALE L, et al. Pulmonary arterial hypertension. Presse Med. 2023;52(3):104168.
[2] GHOFRANI HA, GOMBERG-MAITLAND M, ZHAO L, et al. Mechanisms and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2025; 22(2):105-120.
[3] LUNA-LÓPEZ R, RUIZ MARTÍN A, ESCRIBANO SUBÍAS P. Pulmonary arterial hypertension. Med Clin (Barc). 2022;158(12):622-629.
[4] REINDERS S, DIDDEN EM, ONG R. Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies. Respir Res. 2024;25(1):373.
[5] CHIN KM, GAINE SP, GERGES C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325.
[6] PENG D, FU M, WANG M, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21(1):104.
[7] DENG Z, FAN T, XIAO C, et al. TGF-β signaling in health, disease, and therapeutics. Signal Transduct Target Ther. 2024;9(1):61.
[8] LARSON C, ORONSKY B, CARTER CA, et al. TGF-beta: a master immune regulator. Expert Opin Ther Targets. 2020;24(5):427-438.
[9] AASHAQ S, BATOOL A, MIR SA, et al. TGF-β signaling: A recap of SMAD-independent and SMAD-dependent pathways. J Cell Physiol. 2022;237(1): 59-85.
[10] WENG L, YE J, YANG F, et al. TGF-β1/SMAD3 Regulates Programmed Cell Death 5 That Suppresses Cardiac Fibrosis Post-Myocardial Infarction by Inhibiting HDAC3. Circ Res. 2023;133(3):237-251.
[11] FAN M, YANG K, WANG X, et al. Lactate promotes endothelial-to-mesenchymal transition via Snail1 lactylation after myocardial infarction. Sci Adv. 2023;9(5):eadc9465.
[12] GUIGNABERT C, HUMBERT M. Targeting transforming growth factor-β receptors in pulmonary hypertension. Eur Respir J. 2021;57(2):2002341.
[13] BOUCHET C, CARDOUAT G, DOUARD M, et al. Inflammation and Oxidative Stress Induce NGF Secretion by Pulmonary Arterial Cells through a TGF-β1-Dependent Mechanism. Cells. 2022;11(18):2795.
[14] XIE SS, DENG Y, GUO SL, et al. Endothelial cell ferroptosis mediates monocrotaline-induced pulmonary hypertension in rats by modulating NLRP3 inflammasome activation. Sci Rep. 2022;12(1):3056.
[15] MORALES-CANO D, IZQUIERDO-GARCÍA JL, BARREIRA B, et al. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model. Front Pharmacol. 2023;14:1021535.
[16] ORNATOWSKI W, LU Q, YEGAMBARAM M, et al. Complex interplay between autophagy and oxidative stress in the development of pulmonary disease. Redox Biol. 2020;36:101679.
[17] MARON BA, ABMAN SH, ELLIOTT CG, et al. Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. Am J Respir Crit Care Med. 2021;203(12):1472-1487.
[18] HONG J, MEDZIKOVIC L, SUN W, et al. Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension. Circulation. 2024;150(16):1268-1287.
[19] WITS M, BECHER C, DE MAN F, et al. Sex-biased TGFβ signalling in pulmonary arterial hypertension. Cardiovasc Res. 2023;119(13):2262-2277.
[20] HUMBERT M, MCLAUGHLIN V, GIBBS JSR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021;384(13): 1204-1215.
[21] GAO RJ, AIKEREMU N, CAO N, et al. Quercetin regulates pulmonary vascular remodeling in pulmonary hypertension by downregulating TGF-β1-Smad2/3 pathway. BMC Cardiovasc Disord. 2024;24(1):535.
[22] SONG Y, WEI J, LI R, et al. Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling. Hepatology. 2023;78(5):1433-1447.
[23] ZHANG T, HE X, CALDWELL L, et al. NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling. Sci Transl Med. 2022;14(637):eaaz4028.
[24] HU HH, CHEN DQ, WANG YN, et al. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018;292:76-83.
[25] HAO M, GUAN Z, ZHANG Z, et al. Atractylodinol prevents pulmonary fibrosis through inhibiting TGF-β receptor 1 recycling by stabilizing vimentin. Mol Ther. 2023;31(10):3015-3033.
[26] BAI J, QIAN B, CAI T, et al. Aloin Attenuates Oxidative Stress, Inflammation, and CCl-Induced Liver Fibrosis in Mice: Possible Role of TGF-β/Smad Signaling. J Agric Food Chem. 2023;71(49):19475-19487.
[27] PULLAMSETTI SS, SITAPARA R, OSTERHOUT R, et al. Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension. Int J Mol Sci. 2023;24(16):12653.
[28] REDZA-DUTORDOIR M, AVERILL-BATES DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta. 2016;1863(12):2977-2992.
[29] YANG DP, DONG WP, YANG YC, et al. Tetramethylpyrazine Improves Monocrotaline-Induced Pulmonary Hypertension through the ROS/iNOS/PKG-1 Axis. J Healthc Eng. 2022;2022:1890892.
[30] XU D, HU YH, GOU X, et al. Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension. Molecules. 2022;27(12):3724.
[31] SUN X, LU Q, YEGAMBARAM M, et al. TGF-β1 attenuates mitochondrial bioenergetics in pulmonary arterial endothelial cells via the disruption of carnitine homeostasis. Redox Biol. 2020;36:101593.
[32] TIAN L, WU D, DASGUPTA A, et al. Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension: A Pyruvate Dehydrogenase Kinase-Dependent Shift in Mitochondrial Metabolism Promotes Right Ventricular Fibrosis. Circ Res. 2020;126(12):1723-1745.
[33] ŽOLDÁKOVÁ M, NOVOTNÝ M, KHAKUREL KP, et al. Hemoglobin Variants as Targets for Stabilizing Drugs. Molecules. 2025;30(2):385.
[34] KATSUMURA KR, DEVILBISS AW, POPE NJ, et al. Transcriptional mechanisms underlying hemoglobin synthesis. Cold Spring Harb Perspect Med. 2013; 3(9):a015412.
[35] BUEHLER PW, SWINDLE D, PAK DI, et al. Murine models of sickle cell disease and beta-thalassemia demonstrate pulmonary hypertension with distinctive features. Pulm Circ. 2021;11(4):20458940211055996.
[36] JUAITI M, FENG Y, TANG Y, et al. Integrated bioinformatics analysis and experimental animal models identify a robust biomarker and its correlation with the immune microenvironment in pulmonary arterial hypertension. Heliyon. 2024;10(8):e29587.
[37] TAKEUCHI O, KAWAI T, SANJO H, et al. TLR6: A novel member of an expanding toll-like receptor family. Gene. 1999;231(1-2):59-65.
[38] WANG S, SOLENOV EI, YANG B. Aquaporin Inhibitors. Adv Exp Med Biol. 2023;1398:317-330.
[39] GUSDON AM, VOTYAKOVA TV, REYNOLDS IJ, et al. Nuclear and mitochondrial interaction involving mt-Nd2 leads to increased mitochondrial reactive oxygen species production. J Biol Chem. 2007;282(8):5171-5179. |